Amaryl 3 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

amaryl 3 mg tabletti

sanofi oy - glimepiride - tabletti - 3 mg - glimepiridi

TAVANIC 5 mg/ml infuusioneste, liuos 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

tavanic 5 mg/ml infuusioneste, liuos

sanofi oy - levofloxacini hemihydricum - infuusioneste, liuos - 5 mg/ml - levofloksasiini

Cardace 10 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

cardace 10 mg tabletti

sanofi oy - ramipril - tabletti - 10 mg - ramipriili

Repevax injektioneste, suspensio, esitäytetty ruisku 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

repevax injektioneste, suspensio, esitäytetty ruisku

sanofi pasteur europe - poliovirus type 1, inactivated, poliovirus type 2, inactivated, poliovirus type 3, inactivated, bordetella pertussis toxoid, adsorbed, bordetella pertussis filamentous haemagglutinin, adsorbed, bordetella pertussis pertactin, adsorbed, corynebacterium diphtheriae toxoid, adsorbed, clostridium tetani toxoid, adsorbed, bordetella pertussis fimbriae, adsorbed - injektioneste, suspensio, esitäytetty ruisku - kurkkumätä-

Amaryl 4 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

amaryl 4 mg tabletti

sanofi oy - glimepiride - tabletti - 4 mg - glimepiridi

ZOLMITRIPTAN SANOFI-AVENTIS 2.5 mg tabletti, kalvopäällysteinen 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

zolmitriptan sanofi-aventis 2.5 mg tabletti, kalvopäällysteinen

sanofi-aventis oy - zolmitriptanum - tabletti, kalvopäällysteinen - 2.5 mg - tsolmitriptaani

ZOLMITRIPTAN SANOFI-AVENTIS 2.5 mg tabletti, suussa hajoava 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

zolmitriptan sanofi-aventis 2.5 mg tabletti, suussa hajoava

sanofi-aventis oy - zolmitriptanum - tabletti, suussa hajoava - 2.5 mg - tsolmitriptaani

VAPRINO 100 mg kapseli, kova 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

vaprino 100 mg kapseli, kova

sanofi oy - racecadotrilum - kapseli, kova - 100 mg - rasekadotriili

Sarclisa 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Supemtek 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenssa, ihminen - rokotteet - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.